Structure and molecular modeling of GABAA receptor antagonists.
The recently described potent and selective GABAA antagonist SR 95531 (gabazine) is compared to six other GABAA antagonists: (+)-bicuculline, (-)-securinine, (+)-tubocurarine, iso-THAZ, R-5135, and pitrazepine. Starting from ab initio molecular orbital calculations performed on crystal atomic coordinates, attempts were made to identify in each structure the functional groups that are involved in receptor recognition and binding. A molecular modeling study revealed that (a) all compounds possess accessible cationic and anionic sites separated by an 4.6-5.2 A intercharge distance, (b) the antagonistic nature of the compounds can be explained by the presence of additional binding sites, (c) the correct spatial orientation of the additional binding sites is crucial for GABAA selectivity, and (d) the criteria determining the potency of the antagonist effect are an accurate intercharge distance (greater than 5 A) and the existence of hydrogen-bonding functionalities on one of the additional ring system. The presented pharmacophore accounts also for the inactivity of closely related compounds such as (-)-bicuculline, adlumidine, virosecurinine, allosecurinine, and the 4,6-diphenyl analogue of gabazine.
Rognan
D
D
Laboratories de Pharmacochimie Moléculaire, Université Louis Pasteur, Strasbourg, France.
Boulanger
T
T
Hoffmann
R
R
Vercauteren
D P
DP
Andre
J M
JM
Durant
F
F
Wermuth
C G
CG
D000470:Alkaloids / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D000731:Androstanes / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D001378:Azasteroids / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D001381:Azepines; D001640:Bicuculline / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D003460:Crystallization; D003984:Dibenzazepines / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D058787:GABA-A Receptor Antagonists; D006576:Heterocyclic Compounds, 4 or More Rings; D006572:Heterocyclic Compounds, Bridged-Ring; D007555:Isoxazoles / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D007783:Lactones; D008958:Models, Molecular; D008968:Molecular Conformation; D015394:Molecular Structure; D010880:Piperidines; D011724:Pyridazines / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D011963:Receptors, GABA-A / Q000378:metabolism; D013329:Structure-Activity Relationship; D014403:Tubocurarine / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D014961:X-Ray Diffraction; D005680:gamma-Aminobutyric Acid / Q000737:chemistry
D000470:Alkaloids; D000731:Androstanes; D001378:Azasteroids; D001381:Azepines; D003984:Dibenzazepines; D058787:GABA-A Receptor Antagonists; D006576:Heterocyclic Compounds, 4 or More Rings; D006572:Heterocyclic Compounds, Bridged-Ring; D007555:Isoxazoles; D007783:Lactones; D010880:Piperidines; D011724:Pyridazines; D011963:Receptors, GABA-A; D005680:gamma-Aminobutyric Acid; C041650:isothaz; C041662:pitrazepin; C049853:gabazine; C000785:securinine; C032061:RU 5135; D014403:Tubocurarine; D001640:Bicuculline